Profile data is unavailable for this security.
About the company
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd i is engaged in the pharmaceutical and healthcare industry. The Company's segments are Great Southern TCM, Great Commerce, Great Health and Great Medical Care. The Company's Great South TCM includes research, development, manufacturing and sales for Chinese and western medicine, chemical raw medicine, natural drug, biological medicine and intermediates of chemical raw medicine. The Company's Great Health segment includes the research, development, manufacturing and sales of beverages, foods, health products and other products. The Company's Great Commerce segment includes wholesale, retail, import and export for western medicine, Chinese medicine and medical apparatus and instruments. The Great Medical segment is engaged in medical services, traditional Chinese medicine health preservation, modern pension and medical equipment industry.
- Revenue in HKD (TTM)82.06bn
- Net income in HKD3.68bn
- Incorporated1997
- Employees28.05k
- LocationGuangzhou Baiyunshan Pharmaceutical Holdings Co LtdNo. 45 Shamian North StreetLiwan DistrictGUANGZHOU 510130ChinaCHN
- Phone+86 2 066281218
- Fax+86 2 066281229
- Websitehttp://www.gybys.com.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HUTCHMED (China) Ltd | 4.75bn | -326.67m | 24.32bn | 1.97k | -- | 4.22 | -- | 5.11 | -0.3887 | -0.3887 | 5.51 | 6.61 | 0.4775 | 7.10 | 4.15 | 2,391,453.00 | -3.30 | -14.35 | -4.65 | -20.43 | 41.67 | 36.57 | -6.91 | -31.44 | 2.68 | -- | 0.0984 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| WuXi XDC Cayman Inc | 3.00bn | 638.66m | 31.19bn | 1.50k | 49.55 | 4.84 | 42.88 | 10.39 | 0.5247 | 0.5247 | 2.65 | 5.37 | 0.5586 | 21.31 | 2.85 | 2,549,222.00 | 11.88 | -- | 15.43 | -- | 30.96 | -- | 21.27 | -- | 4.02 | -- | 0.0113 | -- | 114.44 | -- | 82.07 | -- | -- | -- |
| China Resources Pharmaceutical Group Ltd | 269.14bn | 4.06bn | 33.49bn | 72.76k | 8.26 | 0.6445 | 2.70 | 0.1244 | 0.6455 | 0.6455 | 42.84 | 8.27 | 0.966 | 6.09 | 3.28 | 3,687,543.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
| Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 82.06bn | 3.68bn | 47.66bn | 28.05k | 7.99 | 0.7546 | -- | 0.5808 | 2.26 | 2.26 | 50.47 | 23.93 | 0.9946 | 6.07 | 4.60 | 2,925,648.00 | 4.71 | 5.90 | 8.93 | 12.40 | 16.55 | 18.70 | 4.74 | 5.56 | 1.15 | -- | 0.317 | 30.02 | 6.68 | 12.32 | 2.25 | 3.34 | 27.75 | -- |
| CSPC Pharmaceutical Group Ltd | 32.52bn | 5.54bn | 60.70bn | 20.30k | 11.08 | -- | 32.62 | 1.87 | 0.4685 | 0.4685 | 2.75 | -- | -- | -- | -- | 1,383,707.00 | -- | 16.08 | -- | 21.57 | 70.59 | 72.95 | 17.28 | 19.63 | -- | 25.15 | -- | 35.51 | 1.66 | 12.16 | -3.58 | 13.77 | -2.58 | 25.33 |
| Innovent Biologics Inc | 8.01bn | -1.38bn | 63.06bn | 5.26k | -- | 4.70 | -- | 7.87 | -0.8626 | -0.8626 | 5.00 | 8.20 | 0.3905 | 1.32 | 6.25 | 1,644,105.00 | -6.71 | -13.06 | -8.22 | -15.85 | 82.44 | 84.51 | -17.18 | -43.44 | 2.51 | -6.91 | 0.2123 | -- | 36.21 | 265.79 | 52.83 | -- | 34.60 | -- |
| Sino Biopharmaceutical Ltd | 28.78bn | 2.15bn | 63.51bn | 24.44k | 29.02 | 1.76 | 10.22 | 2.21 | 0.1165 | 0.2384 | 1.56 | 1.92 | 0.4050 | 2.37 | 3.74 | 1,115,435.00 | 7.42 | 13.11 | 14.50 | 21.74 | 82.92 | 80.37 | 18.33 | 27.47 | 1.07 | 18.13 | 0.1868 | 25.02 | 0.6657 | 4.63 | -10.29 | -27.22 | -7.18 | 1.15 |
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 01 Nov 2024 | 19.76m | 8.99% |
| LSV Asset Managementas of 31 Dec 2023 | 13.19m | 6.00% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 8.07m | 3.67% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 3.75m | 1.70% |
| HBM Partners AG (Investment Management)as of 31 Mar 2024 | 2.61m | 1.19% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2024 | 1.92m | 0.87% |
| Goldman Sachs Asset Management LPas of 08 Nov 2024 | 1.77m | 0.81% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2024 | 1.52m | 0.69% |
| First Seafront Fund Management Co., Ltd.as of 30 Jun 2024 | 876.00k | 0.40% |
| Mellon Investments Corp.as of 08 Nov 2024 | 864.00k | 0.39% |
